Toggle Main Menu Toggle Search

Open Access padlockePrints

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Lookup NU author(s): Professor David Burn

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and efficacy of davunetide in patients with PSP.Methods In a double-blind, parallel group, phase 2/3 trial, participants were randomly assigned with permuted blocks in a 1:1 ratio to davunetide (30 mg twice daily, intranasally) or placebo for 52 weeks at 48 centres in Australia, Canada, France, Germany, the UK, and the USA. Participants met the modified Neuroprotection and Natural History in Parkinson Plus Syndrome study criteria for PSP. Primary endpoints were the change from baseline in PSP Rating Scale (PSPRS) and Schwab and England Activities of Daily Living (SEADL) scale at up to 52 weeks. All participants and study personnel were masked to treatment assignment. Analysis was by intention to treat. The trial is registered with Clinicaltrials.gov, number NCT01110720.Findings 313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77%) completed the study (118 and 156 in the davunetide and placebo groups, respectively). There were no differences in the davunetide and placebo groups in the baseline PSPRS and SEADL. The davunetide and placebo groups did not differ in the change from baseline in P SPRS (median 11.8 [95% CI 10.5 to 13.0] vs 11.8 [10.5 to 13.0], respectively, p=0.41) or SEADL (-0.20 [-0.20 to -0.17] vs -0.20 [-0.22 to -0.17], respectively, p=0.92). 54 serious adverse events were reported in each of the treatment groups, including 11 deaths in the davunetide group and ten in the placebo group. The frequency of nasal adverse events was greater in the davunetide group than in the placebo group (epistaxis 18 [12%] of 156 vs 13 [8%] of 156, rhinorrhoea 15 [10%] vs eight [5%], and nasal discomfort 15 [10%] vs one [4%]).Interpretation Davunetide is not an effective treatment for PSP. Clinical trials of disease-modifying treatment are feasible in patients with PS P and should be pursued with other promising tau-directed treatments.


Publication metadata

Author(s): Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Hoglinger GU, Koestler M, Jack CR, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH

Publication type: Article

Publication status: Published

Journal: Lancet Neurology

Year: 2014

Volume: 13

Issue: 7

Pages: 676-685

Print publication date: 27/05/2014

ISSN (print): 1474-4422

ISSN (electronic): 1474-4465

Publisher: Elsevier Science

URL: http://dx.doi.org/10.1016/S1474-4422(14)70088-2

DOI: 10.1016/S1474-4422(14)70088-2


Altmetrics

Altmetrics provided by Altmetric


Share